Tag: Remdesivir (Drug)

Remdesivir Coronavirus Trial: Federal Scientists Finally Publish Data

Nearly a month after federal scientists claimed that an experimental drug had helped patients severely ill with the coronavirus, the research has been published. The drug, remdesivir, was quickly authorized by the Food and Drug Administration for treatment of coronavirus patients, and hospitals rushed to obtain supplies. But until now, researchers and physicians had not […]

Read More

How Upbeat Vaccine News Fueled a Stock Surge, and an Uproar

When the biotech company Moderna announced early on Monday morning positive results from a small, preliminary trial of its coronavirus vaccine, the company’s chief medical officer described the news as a “triumphant day for us.” Moderna’s stock price jumped as much as 30 percent. Its announcement helped lift the stock market and was widely reported […]

Read More

Can ‘Team Science’ Yield a Covid-19 Treatment?

ImageCredit…Illustration by Ori Toor Xin Yin was excited to be visiting his parents in the Shandong Province of China last December. Yin, a researcher in the Immunity and Pathogenesis Program at the Sanford Burnham Prebys Medical Discovery Institute in California, hadn’t been home in five years. So much had changed since then — a new […]

Read More

Haphazard Rollout of Coronavirus Drug Frustrates Doctors

When the Food and Drug Administration granted an emergency approval last week for an antiviral drug, remdesivir, to treat hospitalized coronavirus patients, many doctors were overjoyed. The drug is the first shown to be even mildly effective against the virus. But bafflement soon followed as doctors and hospitals tried to obtain the drug. Small community […]

Read More

Global Race for a Coronavirus Vaccine Intensifies

WASHINGTON — Four months after a mysterious new virus began its deadly march around the globe, the search for a vaccine has taken on an intensity never before seen in medical research, with huge implications for public health, the world economy and politics. Seven of the roughly 90 projects being pursued by governments, pharmaceutical makers, […]

Read More

How Remdesivir, New Hope for Covid-19 Patients, Was Resurrected

Remdesivir, an antiviral drug designed to treat both hepatitis and a common respiratory virus, seemed fated to join thousands of other failed medications after proving useless against those diseases. The drug was consigned to the pharmaceutical scrap heap, all but forgotten by the scientists who once championed it. But on Friday, the Food and Drug […]

Read More

What Do We Know About Coronavirus? There Will Be Mistakes

It might seem surprising, but we find reassurance in this topsy-turvy Covid-19 news cycle. In fact, we need more of it. Every new test should be compared to the others available, even though that means finding that some are inaccurate. We must assess every treatment to see if it is better than not using it […]

Read More

Stocks Are Rising as Economic News Worsens

Yet by the end of the day, the S&P 500 stock index had risen 2.7 percent. That’s been the pattern lately. The drumbeat of grim news — one million known coronavirus cases in the United States, businesses are collapsing, the unemployment rate could reach 16 percent — has done little to deter stocks’ upward march. […]

Read More

Gilead Claims ‘Positive Data’ to Come From N.I.H. Trial of Remdesivir

Gilead Sciences on Wednesday announced that the company “is aware of positive data” from a federal trial of its experimental coronavirus drug, remdesivir, even as a new study reported that the drug offered no benefit to severely ill patients in China. Neither Gilead nor officials at the National Institute of Allergy and Infectious Diseases, sponsor […]

Read More

The Story of Remdesivir

Diana Brainard is nowhere near close to celebrating. Dr. Brainard is the head of antiviral clinical research at Gilead Sciences, the Bay Area biotech giant whose drug portfolio includes the antiviral medicine remdesivir. On Thursday, Stat, the superb medical-news website, reported some of the leaked results of a pair of Phase 3 clinical trials of […]

Read More

Despite Qualms, Arthritis Drug Is to Be Tested in Coronavirus Study

An Eli Lilly drug for rheumatoid arthritis carries a warning on its label saying patients with infections should not take it because it can make infections worse. Yet the National Institutes of Health is about to test it in people hospitalized with coronavirus infections. The study, whose innovative design is meant to find out — […]

Read More

Pharmaceutical Profits and Fighting Corona Are Not Incompatible

The rapid spread of the coronavirus has revived a decades-old debate over pharmaceutical policy, with both sides doubling down on long-held views. Advocates for broader drug access insist that pharmaceutical companies must not be allowed to reap large profits from Covid-19 vaccines and treatments. Free-market true believers — including officials in the Trump administration — […]

Read More

How New Jersey’s First Coronavirus Patient Survived

Listen to This Audio Audio Recording by Audm To hear more audio stories from publishers, like The New York Times, download Audm for iPhone or Android. On the evening of March 4, James Cai, a 32-year-old physician assistant, was languishing on a cot, isolated in a small, windowless room on the emergency-room floor of Hackensack […]

Read More

Gilead Withdraws Request for Special Orphan Status on Experimental Coronavirus Treatment

Bowing to criticism that it was exploiting the coronavirus pandemic, the drugmaker Gilead said on Wednesday that it would no longer seek orphan-drug status for remdesivir, an experimental drug that is being tested as a possible treatment. The Food and Drug Administration had only granted the special designation on Monday — which gives drug companies […]

Read More